Actively Recruiting
Phase 2 Study of Lenvatinib and Tislelizumab with Gemcitabine and Cisplatin for Advanced Cholangiocarcinoma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a combination treatment using lenvatinib, tislelizumab, gemcitabine, and cisplatin GPLET in patients with advanced cholangiocarcinoma, a group of aggressive cancers arising from bile duct cells. This phase 2, open-label study aims to investigate how this combination impacts tumor response and survival compared to gemcitabine plus cisplatin alone. The rationale is based on the potential for these drugs to enhance the immune systems ability to fight cancer by reducing tumor immunosuppression and triggering strong anti-tumor T cell responses. Participants receive intravenous gemcitabine and cisplatin on days 1 and 8 of each 21-day cycle. Those in the experimental group also take oral lenvatinib daily 8 mg if under 60 kg or 12 mg if 60 kg or more from days 1 to 21, and receive an intravenous dose of tislelizumab on day 15. The control group receives only gemcitabine and cisplatin. Treatment cycles repeat every 21 days, and the study monitors patients through multiple cycles. During the study, participants will undergo evaluations of tumor response after four treatment cycles to measure objective remission rate. Researchers will also track progression-free survival and overall survival for up to 60 months. Safety assessments and regular monitoring of organ and bone marrow function are included. The total study duration allows for long-term follow-up to understand the treatments impact on disease progression and patient outcomes.
CONDITIONS
Brief Title
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here